Xevudy

Xevudy (sotrovimab) is an antiviral medication used to treat mild-to-moderate COVID-19 in adults and adolescents. Administered via intravenous infusion, it targets SARS-CoV-2 to reduce symptom severity. This overview covers key details for informed use. Seek medical guidance for personalized advice.

Xevudy (sotrovimab) is designed for people with confirmed COVID-19 who are at high risk of severe illness. It works by binding to the spike protein of the virus, helping the immune system neutralize the infection. This treatment is intended for early use in mild-to-moderate cases to prevent progression. It is not a substitute for vaccination.

After receiving Xevudy, some patients report temporary relief from COVID-19 symptoms such as fever, cough, or fatigue. The infusion process may cause mild discomfort at the injection site. Most effects are short-lived and monitored during administration. Individual responses vary based on health status and timing of treatment.

Xevudy should be administered under medical supervision in a healthcare setting. Patients with a history of severe allergic reactions to its components should avoid it. Inform your provider about current medications or conditions before treatment. Stay hydrated and follow post-infusion care instructions as directed.

Xevudy may interact with other monoclonal antibodies or immunosuppressants, potentially altering effectiveness. Caution is advised when combining with drugs that affect the immune system. No specific food or alcohol restrictions are noted, but discuss all medications with your healthcare provider. Monitor for unexpected reactions during and after infusion.